Volume 73, Issue 2, Pages (February 2018)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Volume 62, Issue 3, Pages (September 2012)

Volume 155, Issue 3, Pages (March 1996)

The PSA Era is not Over for Prostate Cancer

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 62, Issue 4, Pages (October 2012)

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 59, Issue 5, Pages (May 2011)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 68, Issue 3, Pages (September 2015)

EAU Guidelines on Testicular Cancer: 2011 Update

Ashish M. Kamat, Sima Porten European Urology

Volume 68, Issue 1, Pages (July 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 72, Issue 5, Pages (November 2017)

Volume 59, Issue 2, Pages (February 2011)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 5, Pages (November 2007)

Volume 61, Issue 4, Pages (April 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Prostate Cancer Detection: A View of the Future

Volume 67, Issue 3, Pages (March 2015)

Volume 70, Issue 4, Pages (October 2016)

Volume 64, Issue 5, Pages (November 2013)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 2, Pages (February 2008)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 4, Pages (October 2013)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 74, Issue 2, Pages (August 2018)

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Volume 71, Issue 4, Pages (April 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 61, Issue 5, Pages (May 2012)

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 52, Issue 6, Pages (December 2007)

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

Testicular Cancer Variations in Time and Space in Europe

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

European Urology is “Your” Journal

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Volume 52, Issue 4, Pages (October 2007)

Volume 53, Issue 6, Pages (June 2008)

Volume 51, Issue 2, Pages (February 2007)

Volume 52, Issue 1, Pages (July 2007)

Penile and Testicular Cancer: What's New in 2006?

Jan Roigas European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 73, Issue 2, Pages 262-270 (February 2018) Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, Mark A. Preston, Quoc-Dien Trinh, Lindsay A. Frazier, Toni K. Choueiri, Neil E. Martin, Paul L. Nguyen, Clair J. Beard European Urology Volume 73, Issue 2, Pages 262-270 (February 2018) DOI: 10.1016/j.eururo.2017.06.013 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Flowchart that describes the selection of patients who received adjuvant treatment versus observation for clinical stage IS seminomatous and nonseminomatous germ cell tumor of the testis in the National Cancer Data Base, 2004–2012. NCCN=National Comprehensive Cancer Network. European Urology 2018 73, 262-270DOI: (10.1016/j.eururo.2017.06.013) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Treatment trends for clinical stage IS (A) seminomatous and (B) nonseminomatous germ cell tumor of the testis comparing the proportion of adjuvant treatment versus observation from 2004 to 2012. European Urology 2018 73, 262-270DOI: (10.1016/j.eururo.2017.06.013) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Inverse probability treatment weighting-adjusted Kaplan-Meier analysis of overall survival in patients who received adjuvant treatment versus observation for (A) seminomatous and (B) nonseminomatous germ cell tumor of the testis. European Urology 2018 73, 262-270DOI: (10.1016/j.eururo.2017.06.013) Copyright © 2017 European Association of Urology Terms and Conditions